{"organizations": [], "uuid": "0077ffe3913e8cd769ee3c017abc991da1a51868", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/novartis-ms-approval/novartis-gets-u-s-approval-for-bigger-dose-glatopa-ms-treatment-idUSFWN1Q301S", "country": "US", "domain_rank": 408, "title": "Novartis gets U.S. approval for bigger dose Glatopa MS treatment", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-13T14:57:00.000+02:00", "replies_count": 0, "uuid": "0077ffe3913e8cd769ee3c017abc991da1a51868"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/novartis-ms-approval/novartis-gets-u-s-approval-for-bigger-dose-glatopa-ms-treatment-idUSFWN1Q301S", "ord_in_thread": 0, "title": "Novartis gets U.S. approval for bigger dose Glatopa MS treatment", "locations": [], "entities": {"persons": [{"name": "sunil nair", "sentiment": "none"}, {"name": "john revill", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "zurich", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "novartis", "sentiment": "negative"}, {"name": "sandoz", "sentiment": "negative"}, {"name": "food and drugs administration", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "ZURICH, Feb 13 (Reuters) - Novartisâ€™s Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.\nThe Food and Drugs Administration has approved the use of 40 milligrams per milliliter injection, taken three times per week, as a fully suitable generic version of the standard Copaxone treatment, the company said.\nSandoz had already offered the 20 mg/ml dosage to U.S. patients with relapsing forms of multiple sclerosis since 2015.\nReporting by John Revill; Editing by Sunil Nair\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-13T14:57:00.000+02:00", "crawled": "2018-02-14T12:29:02.002+02:00", "highlightTitle": ""}